Resistance to Rituximab Therapy and Local BAFF Overexpression in Sjögren’s Syndrome-Related Myoepithelial Sialadenitis and Low-Grade Parotid B-Cell Lymphoma

OBJECTIVE: B-cell expansion is a key feature of Sjögren’s syndrome (SS). Accordingly, several studies have reported the benefits of B-cell depletion with anti-CD20 monoclonal antibody (Rituximab) in the treatment of glandular and extraglandular manifestations of SS. Patients with SS are at increased...

Descripción completa

Detalles Bibliográficos
Autores principales: Quartuccio, Luca, Fabris, Martina, Moretti, Massimo, Barone, Francesca, Bombardieri, Michele, Rupolo, Maurizio, Lombardi, Sandra, Pitzalis, Costantino, Beltrami, Carlo Alberto, Curcio, Francesco, De Vita, Salvatore
Formato: Texto
Lenguaje:English
Publicado: Bentham Open 2008
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2577948/
https://www.ncbi.nlm.nih.gov/pubmed/19088870
http://dx.doi.org/10.2174/1874312900802010038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2577948/
https://www.ncbi.nlm.nih.gov/pubmed/19088870
http://dx.doi.org/10.2174/1874312900802010038

Ejemplares similares